Journal Article

Anti-TNF (adalimumab) injection for the treatment of pain-predominant early-stage frozen shoulder: the Anti-Freaze-Feasibility randomised controlled trial

Francis, Anne, Hopewell, Sally, Lamb, Sarah, Er, Fema, Feldmann, Marc, Rangan, Amar, Evans, Alison, Nanchahal, Jagdeep, Srikesavan, Cynthia, Preece, Jane, Massa, M Sofia

2024

Overview

ObjectiveThe Anti-Freaze-F (AFF) trial assessed the feasibility of conducting a definitive trial to determine whether intra-articular injection of adalimumab can reduce pain and improve function in people with pain-predominant early-stage frozen shoulder.DesignMulticentre, randomised feasibility trial, with embedded qualitative study.SettingFour UK National Health Service (NHS) musculoskeletal and related physiotherapy services.ParticipantsAdults ≥18 years with new episode of shoulder pain attributable to early-stage frozen shoulder.InterventionsParticipants were randomised (centralised computer generated 1:1 allocation) to either ultrasound-guided intra-articular injection of: (1) adalimumab (160 mg) or (2) placebo (saline (0.9% sodium chloride)). Participants and outcome assessors were blinded to treatment allocation. Second injection of allocated treatment (adalimumab 80 mg) or equivalent placebo was administered 2–3 weeks later.Primary feasibility objectives(1) Ability to screen and identify participants; (2) willingness of eligible participants to consent and be randomised; (3) practicalities of delivering the intervention; (4) SD of the Shoulder Pain and Disability Index (SPADI) score and attrition rate at 3 months.ResultsBetween 31 May 2022 and 7 February 2023, 156 patients were screened of whom 39 (25%) were eligible. The main reasons for ineligibility were other shoulder disorder (38.5%; n=45/117) or no longer in pain-predominant frozen shoulder (33.3%; n=39/117). Of the 39 eligible patients, nine (23.1%) consented to be randomised (adalimumab n=4; placebo n=5). The main reason patients declined was because they preferred receiving steroid injection (n=13). All participants received treatment as allocated. The mean time from randomisation to first injection was 12.3 (adalimumab) and 7.2 days (placebo). Completion rates for patient-reported and clinician-assessed outcomes were 100%.ConclusionThis study demonstrated that current NHS musculoskeletal physiotherapy settings yielded only small numbers of participants, too few to make a trial viable. This was because many patients had passed the early stage of frozen shoulder or had already formulated a preference for treatment.Trial registration numberISRCTN 27075727, EudraCT 2021-03509-23, ClinicalTrials.gov NCT05299242 (REC 21/NE/0214).

• Publisher: British Medical Journal Publishing Group,BMJ Publishing Group LTD,BMJ Publishing Group
• Subject: Adalimumab - administration & dosage / Adalimumab - therapeutic use / Adult / Aged / Anticoagulants / Arthritis / Bursitis - drug therapy / Consent / Feasibility / Feasibility Studies / Female / Humans / Injections, Intra-Articular / Male / Manipulative therapy / Middle Aged / Monoclonal antibodies / Musculoskeletal disorders / Pain / Pain Measurement / Patients / Physical therapy / Primary care / Qualitative research / Range of motion / Rehabilitation medicine / Shoulder / Shoulder Pain - drug therapy / Shoulder Pain - etiology / Steroids / Systematic review / Treatment Outcome / Tumor necrosis factor-TNF / Ultrasonic imaging / Ultrasonography, Interventional / United Kingdom